3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Carcinoma, Non-Small-Cell Lung
1
BRAF V600E Mutation
1
Interventions
Cytarabine
14
Cyclophosphamide
12
Whole-Body Irradiation
10
Methotrexate
9
venetoclax
8
fludarabine
7
Vincristine
7
Specimen Handling
7
Mycophenolic Acid
7
Dexamethasone
7
fludarabine phosphate
6
Idarubicin
5
Hydrocortisone
5
Daunorubicin
5
Calcium Dobesilate
5
Biopsy
5
Azacitidine
5
revumenib
4
calaspargase pegol
4
blinatumomab
4
X-Rays
4
Stem Cell Transplantation
4
Peripheral Blood Stem Cell Transplantation
4
Mercaptopurine
4
Filgrastim
4
Cyclosporins
4
Cyclosporine
4
Cladribine
4
pegylated granulocyte colony-stimulating factor
3
dexamethasone acetate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, Biphenotypic, Acute
×
Cobicistat
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA